Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Jonathan Rees and colleagues in the Surgical Intervention Trials Unit (SITU) have just been awarded a £1.5 million National Institute of Health Research HTA grant for the PRoCuRe trial to explore the benefits of surgical repair of partial rotator cuff tendon tears of the shoulder.

Professor Jonathan Rees

Rotator cuff problems are the most common cause of shoulder pain and disability, affecting people with day to day activities, work, recreation and sleep. These tears can be full tears through the whole tendon or only partially through. Partial tears are usually treated in the NHS first with physiotherapy and a steroid injection but then surgery if the patient does not get better.

Professor Rees, Section Head Orthopaedic and Plastic Surgery at the Botnar Research Centre, NDORMS says: "Surgery for full tears is one of the most common shoulder operations in the UK but for partial tears we still don't know if surgical repair gives patients a better result in the short term, or whether it prevents full tears developing in the long term. UK patients and surgeons have prioirtised a need to answer this question which is why this trial has been funded by the HTA."

The PRoCuRe trial will take place across 20 NHS hospitals in the UK, recruiting adult patients , who have partial tears of the rotator cuff tendon and persistent shoulder pain after physiotherapy and injection treatments. The randomised controlled trial will compare arthroscopic (keyhole) surgery that cleans, tidies and repairs the tear, to a procedure that just cleans and tidies the tear. The team will monitor how well patients recover firstly over 2 years and then over 5 years.

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.